人口腔鳞状细胞癌细胞Ca9-22
BLUEFBIO™ Product Sheet
细胞名称 |
人口腔鳞状细胞癌细胞Ca9-22 |
|
|
货物编码 |
BFN60808616 |
||
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
细胞数量 |
1x10^6 |
1x10^6 |
|
保存温度 |
37℃ |
-198℃ |
|
运输方式 |
常温保温运输 |
干冰运输 |
|
安全等级 |
1 |
||
用途限制 |
仅供科研 2类 |
培养体系 |
DMEM高糖+10%FBS+1%三抗 |
||
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
简介 |
人口腔鳞状细胞癌细胞Ca9-22取自43岁男性供体。有报道显示该细胞源头被MSK-922细胞所污染,细胞公认力下降,请各位学者注意。该细胞由我库引种自JCRB,经过STR验证。 |
||
注释 |
Problematic cell line: Partially contaminated. Some stocks of Ca9-22 are contaminated with MSK-922 (PubMed=21868764). Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00437. Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. |
||
基因突变 |
TP53 p.Arg248Trp (c.742C>T) (PubMed=1570156; PubMed=10741724). |
||
HLA信息 |
Class I HLA-A A*02:07,24:02 HLA-B B*35,46:01 HLA-C C*01:02,14:02 |
||
STR信息 |
Amelogenin X,Y CSF1PO 12 D5S818 12 D7S820 11,13 D13S317 11 D16S539 9,10 TH01 6 TPOX 8,11 vWA 16 |
||
参考文献 |
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010)
PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690 Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin. Cancer Res. 17:7248-7264(2011)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016)
PubMed=29156801; DOI=10.18632/oncotarget.21174 Kalu N.N., Mazumdar T., Peng S., Shen L., Sambandam V., Rao X., Xi Y., Li L., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget 8:86369-86383(2017)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) |